Brind.

A drug developed by Roivant/Priovant Therapeutics received FDA approval for the treatment of dermatomyositis.

3 reports, 1 independent Updated Sep 22

Gone quiet

Reports: 3
Developments: 1
Repetition: 67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A drug developed by Roivant/Priovant Therapeutics received FDA approval for the treatment of dermatomyositis.

Who's involved

What this event is mainly about

FDA Roivant Sciences (United States)

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Roivant Sciences (United States)
company in New York, United States

Nothing else this week.

Related events

Roivant Sciences licensed a drug from Pfizer for regulatory approval.Sep 9

Coverage

Newest first; wire copies grouped

Sep 22yahoo.com
Sep 7yahoo.com

1 more outlet ran the same wire story

Sep 22insidermonkey.com